Literature DB >> 12464118

The differential diagnosis of Parkinson's disease.

W Poewe1, G Wenning.   

Abstract

The diagnosis of Parkinson's disease continues to be challenging with misdiagnosis rates as high as 20-30% in early stages. Such diagnostic inaccuracy is largely due to failure to recognize atypical parkinsonian disorders including multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and dementia with Lewy bodies (DLB). These disorders are characterized by distinctive sets of atypical features that have been incorporated into recent consensus diagnostic criteria. Early diagnosis of atypical parkinsonian disorders is important not only because of prognostic implications, but also because of variable therapeutic targets such as autonomic failure, apraxia or dementia.

Entities:  

Mesh:

Year:  2002        PMID: 12464118     DOI: 10.1046/j.1468-1331.9.s3.3.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  29 in total

1.  Who should look after people with Parkinson's disease?

Authors:  Rajendra Kale; Matthew Menken
Journal:  BMJ       Date:  2004-01-10

Review 2.  A generic research paradigm for identification and validation of early molecular diagnostics and new therapeutics in common disorders.

Authors:  Keith D Coon; Travis L Dunckley; Dietrich A Stephan
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

3.  Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging.

Authors:  Y Wang; S R Butros; X Shuai; Y Dai; C Chen; M Liu; E M Haacke; J Hu; H Xu
Journal:  AJNR Am J Neuroradiol       Date:  2011-11-03       Impact factor: 3.825

Review 4.  Early perfusion and dopamine transporter imaging using 18F-FP-CIT PET/CT in patients with parkinsonism.

Authors:  Chae-Moon Hong; Ho-Sung Ryu; Byeong-Cheol Ahn
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-12-20

5.  NMR Metabolomics Analysis of Parkinson's Disease.

Authors:  Shulei Lei; Robert Powers
Journal:  Curr Metabolomics       Date:  2013

6.  Regional volume analysis of the Parkinson disease brain in early disease stage: gray matter, white matter, striatum, and thalamus.

Authors:  S H Lee; S S Kim; W S Tae; S Y Lee; J W Choi; S B Koh; D Y Kwon
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-17       Impact factor: 3.825

7.  Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging.

Authors:  Soyoung Jin; Minyoung Oh; Seung Jun Oh; Jungsu S Oh; Sang Ju Lee; Sun Ju Chung; Chong Sik Lee; Jae Seung Kim
Journal:  Nucl Med Mol Imaging       Date:  2012-11-03

Review 8.  Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.

Authors:  Ilan Halperin; Micaela Morelli; Amos D Korczyn; Moussa B H Youdim; Silvia A Mandel
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

9.  The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism.

Authors:  Mathias Schreckenberger; Stefan Hägele; Thomas Siessmeier; Hans-Georg Buchholz; Heike Armbrust-Henrich; Frank Rösch; Gerhard Gründer; Peter Bartenstein; Thomas Vogt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-23       Impact factor: 9.236

10.  Genome-wide estimate of the heritability of Multiple System Atrophy.

Authors:  M Federoff; T R Price; A Sailer; S Scholz; D Hernandez; A Nicolas; A B Singleton; M Nalls; H Houlden
Journal:  Parkinsonism Relat Disord       Date:  2015-11-05       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.